RxDoctor Payments Data

Ehab Hassanain, MD

General Practice · West Babylon, NYNPI 1700174729

Payments from drug & device makers

$1,518in general payments, 2019–2025

Across 48 payments — averaging $31.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$208
  • GSK$204
  • Esperion Therapeutics, Inc.$194
  • Lilly USA, LLC$188
  • Mannkind Corporation$166
  • AbbVie$161
  • plus $397 from 12 others

What the payments were for

  • Food & beverage$1,518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,518 in reported general payments places this provider in the 85th percentile of 5,764 general practice providers in New York.

See all general practice providers in New York

Medicare billing

Part B allowed, 2024
$61,543
Medicare patients
82
Services billed
1,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide203$227,294
FarxigaDapagliflozin Propanediol125$138,798
TrulicityDulaglutide78$87,888
JardianceEmpagliflozin58$64,223
JanuviaSitagliptin Phosphate38$40,975
XareltoRivaroxaban25$26,519
JanumetSitagliptin Phos/Metformin Hcl27$23,858
EliquisApixaban11$15,681
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$15,510
MounjaroTirzepatide12$11,088
Diclofenac Sodium50$10,621
LinzessLinaclotide16$9,595
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$3,737
SymbicortBudesonide/Formoterol Fumarate14$3,696
Albuterol Sulfate HfaAlbuterol Sulfate138$3,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$93$227,294203 claims
AstraZenecaFarxiga, Symbicort$208$142,494139 claims
Lilly USA, LLCTrulicity, Mounjaro$188$98,97590 claims
MerckJanuvia, Janumet$14$64,83465 claims
Boehringer IngelheimJardiance$18$64,22358 claims
AbbVieLinzess$161$9,59516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,764 general practice providers in New York.

Other general practice in West Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →